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Among the neurodegenerative movement 
disorders, Parkinson’s disease (PD) is the 
most prevalent (Schapira, 2009), affecting 
about 1% of people aged over 55 years, 
with a increase of fivefold by the age of 70, 
characterizing aging as the most impor-
tant risk factor for this pathology (Collier 
et al., 2007). The first description of PD was 
made in 1817 by the British physician James 
Parkinson, who described a syndrome 
mainly characterized by an involuntary 
tremulous motion, defined as a “shaking 
palsy” (Parkinson, 1817). Two forms of PD 
have been identified: a sporadic form, which 
affects most than 90% of all patients and 
whose etiology is still unknown (Tanner, 
2003), and a familial form accounting for 
about 10% remaining, directly linked to 
mutations in specific genes (Dauer and 
Przedborski, 2003).
The main histopathological feature of 
PD is the loss of dopaminergic neurons of 
the substantia nigra pars compacta (SNpc) 
(Dauer and Przedborski, 2003) with a fur-
ther depletion of dopamine in the striatum. 
Degenerating dopaminergic neurons in PD 
are characterized by the presence of the 
accumulation of cytoplasmatic inclusions 
named Lewy bodies, constituted by fibril-
lar proteins alpha-synuclein and ubiquitin 
(Lees et al., 2009). Following the neuronal 
degeneration there is a loss of the striatal 
dopaminergic innervation, which ulti-
mately results in the characteristic motor 
dysfunction observed in PD. In addition 
to the motor dysfunction, cognitive, and 
behavioral alterations are also observed 
in PD, since other neuronal groups are 
affected for instance in the locus coeruleus, 
the nucleus basalis of Meynert, and in later 
stages, in the neocortex (Braak et al., 2003). 
Although these disturbances currently do 
not take part in the diagnostic of PD, animal 
models point that they may emerge earlier 
than the motor disturbs (Da Cunha et al., 
2001).
Though the mechanisms responsible 
for the loss of dopaminergic cells in PD 
are still unclear, there are evidences that 
inflammation, oxidative stress, and exci-
totoxicity are involved in the progression 
of the disease (Dawson and Dawson, 2003; 
Kim and Joh, 2006), albeit these events do 
not be specific to PD since they also con-
tribute to other acute and chronic neuro-
degenerative disorders (Guimarães et al., 
2009). Inflammation seems to be widely 
implicated to neuronal degeneration in PD 
because microglial cells are an important 
source of potentially harmful substances 
such as nitric oxide, free radicals, inter-
leukin 1-beta, and tumor necrosis factor 
alpha (Hirsch and Hunot, 2009; Long-
Smith et al., 2009).
The main dysfunctions of movement 
affecting PD patients are bradykinesia 
(slowless of movement), tremor, rigidity, 
postural instability, and loss of motor 
skills (Gelb et al., 1999). One of the treat-
ments mostly employed to alleviate these 
symptoms is the administration of l-3,4-
dihydroxyphenylalanine (levodopa), the 
dopamine precursor substance. According 
to Olanow et al. (2004) there are two main 
questions related to the action of levo-
dopa: (1) Is it toxic? (2) Its prolonged use 
causes motor complications? Concerning 
the first point, evidences point that levo-
dopa is toxic in cell culture (Mytilineou 
et al., 1993), although this had not been 
reported on in vivo models. Regarding the 
later question, Barroso-Chinea and Bezard 
(2010) contribute with a comprehensive 
review in Frontiers in Neuroanatomy. In 
that article the authors review the gen-
eral organization of the basal ganglia 
and focus on the abnormal disturbance 
of movement developed after a continu-
ous treatment with levodopa, termed 
levodopa-induced dyskinesia. This phe-
nomenon appears to be a “side effect” of 
the prolonged levodopa administration, 
though, as pointed out by the authors, 
some people do not develop this dis-
turb even after several years of levodopa 
treatment. Why this occurs? Even with 
all efforts to understand the basis of the 
phenomenon, it still remains unclear. This 
dual action of levodopa can be exempli-
fied by the control of levels of glutamic 
acid decarboxylase (GAD), the enzyme of 
synthesis of γ-amino butyric acid (GABA), 
in different models of PD. While some 
studies report a decrease of GAD expres-
sion after administration of levodopa, 
others, conversely, attest an increase in its 
expression (Barroso-Chinea and Bezard, 
2010). One hypothesis is that besides of 
its specific action in dopaminergic neu-
rons, levodopa could also be involved with 
metabolic alterations of others neuronal 
groups related to motor control.
Barroso-Chinea and Bezard also high-
light the efforts in the development/use of 
imaging techniques to study the basal gan-
glia, which could be employed as biomark-
ers to, for instance, help in an early-onset 
diagnosis of PD or to characterize the pro-
gression of the disease. The authors cite 
positron emission tomography (PET) and 
single photon emission computed tomog-
raphy (SPECT) as tools capable of provide 
important information regarding the events 
underlying the appearing/progression of the 
PD. In addition, animal models reproducing 
neuropathological/behavioral aspects of PD 
also are important to a better understand-
ing of the alterations observed during this 
disease.
In conclusion, more studies emphasiz-
ing not only the motor deficits but also the 
alterations observed in areas  associative 
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and related to cognition can provide a 
more comprehensive understanding of PD, 
especially correlated to the development of 
more effective drugs to reduce the disturbs 
observed in this pathology or even to a bet-
ter understanding concerning the action of 
drugs already known.
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